SYGGF

Synairgen plc

$0.32

chg

0.00 (0.00%)

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

0.226

52 wk hi

2.88

Cash

$45.7M

Burn Rate (Qtr)

$8.3M

Mkt Cap

$63.6m

Avg Volume

3,681

*cash/burn updated:

Q4 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

SG016 / SNG001

COVID-19

Phase 3

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IFN-β (SNG001)

Psoriasis, Skin disease/disorder

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

SYGGF

BPIQ_Logo_RGB-01.jpg

Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

Recent Posts

See what the community is saying - click to see full post.

SYGGF - Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine

SYGGF (Synairgen) - Positive results from interim analysis of SG015, its double-blind placebo-controlled
Phase II trial of SNG001